Epoetin beta
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Legal status |
|
| Identifiers | |
| ATC code | B03XA01 |
| ChemSpider | none |
| UNII |
64FS3BFH5W  |
 (what is this?) (verify) | |
Epoetin beta (rINN) /ɛˈpoʊ.ᵻtᵻn/ is a synthetic, recombinant[1] form of erythropoietin. It stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Epoetin is marketed under the trade names NeoRecormon.[2]
References
- ↑ Dunn CJ, Markham A (1996). "Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure". Drugs 51 (2): 299–318. doi:10.2165/00003495-199651020-00008. PMID 8808169.
- ↑ Amgen - Products. URL: http://www.amgen.com/patients/prca.html. Accessed on: October 21, 2007.
External links
- Jenkins, John K. (2007-06-26). "Congressional Testimony: Erythropoiesis-Stimulating Agents (ESA)". News & Events. FDA. Retrieved 2010-02-25.
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.